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Human T-cell leukaemia virus type 1 (HTLV-1) causes not only adult T-cell
leukaemia-lymphoma (ATL), but also inflammatory diseases including
HTLV-1-associated myelopathy/tropical spastic paraparesis. HTLV-1 trans-
mits primarily through cell-to-cell contact, and generates abundant infected
cells in the host in order to survive and transmit to a new host. The result-
ing high proviral load is closely associated with the development of ATL
and inflammatory diseases. To increase the number of infected cells,
HTLV-1 changes the immunophenotype of infected cells, induces prolifer-
ation and inhibits apoptosis through the cooperative actions of two viral
genes, tax and HTLV-1 bZIP factor (HBZ). As a result, infected cells survive,
proliferate and infiltrate into the tissues, which is critical for transmission of
the virus. Thus, the strategy of this virus is indivisibly linked with its patho-
genesis, providing a clue for prevention and treatment of HTLV-1-induced
diseases.
This article is part of the themed issue ‘Human oncogenic viruses’.1. Introduction
Human T-cell leukaemia virus type 1 (HTLV-1) has a long history in the
human, after interspecies transmission from monkeys. HTLV-1 has a simian
origin called simian T-cell leukaemia virus type 1 (STLV-1). STLV-1 is endemic
in many species of Old-World monkeys and apes. The precise origins of the
ancestors of HTLV-1 now present in humans remain uncertain, i.e. the species
of monkey and the time and place of the putative interspecies transmission.
However, it is thought to be an ancient interspecies transfer [1]. Moreover, inter-
species transmission from monkeys and apes infected by STLV-1 strains are
continuing, at least in Central Africa, as reported in [2]. In this review, we
show how HTLV-1 transmits and survives in vivo, and how the strategy of
the virus is associated with the pathogenesis of malignant and inflammatory
diseases, with a special focus on adult T-cell leukaemia-lymphoma (ATL).2. The strategy of human T-cell leukaemia virus type 1
One of the most striking characteristics of HTLV-1 is that this virus can transmit
only through cell-to-cell contact [3]. Free virus is not detected in infected individ-
uals, and free virions show very poor infectivity in vitro. Thus, transmission of
this virus needs living infected cells. Infected cells transmit to new hosts through
three routes: breast-feeding, sexual intercourse, and the parenteral route [4].
Therefore, if HTLV-1 can increase the number of infected cells in the host, it
would augment transmission of this virus. Indeed, HTLV-1 generates a high
frequency of infected cells in vivo. For this purpose, HTLV-1-infected cells
need to evade host immune surveillance, promote proliferation and inhibit
rstb.royalsocietypu
2apoptosis. Another important issue for transmission is that
infected cells enter into breast milk and semen for trans-
mission. HTLV-1 has therefore evolved mechanisms to
increase the migratory capacity of infected T cells. These
two broad viral strategies—host cell proliferation and cellular
motility—are closely linked to the pathogenesis of the diseases
caused by this virus [5,6]. blishing.org
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372:201602723. Genetic structure and gene products of
human T-cell leukaemia virus type 1
HTLV-1 has a similar structure to other complex retroviruses.
In addition to structural genes (gag, pol and env), it encodes
regulatory genes (tax and rex) and accessory genes ( p12,
p13, p30 and HTLV-1 bZIP factor (HBZ)) [7]. As shown in
figure 1, only HBZ is encoded on the minus strand of the pro-
virus and transcribed from the 30 long terminal repeat (LTR).
Other viral genes are transcribed as sense transcripts from the
50LTR. Transcription from the 50LTR is highly inducible by
Tax, in which CREB and p300/CBP are involved [8]. Whereas
tax is intermittently transcribed in vivo, HBZ undergoes con-
stant expression, in which SP1 is critically involved [9]. JunD
augments HBZ transcription by cooperating with Sp1 [10].
Tax expression is enhanced by removal of CD8þ T cells
in vitro, suggesting that cytotoxic T lymphocytes (CTLs) sup-
press Tax expression in vivo [11]. These different modes of
transcription may be linked with the immunogenicity of
these proteins. Tax is a highly immunogenic protein, whereas
the immunogenicity of HBZ protein is low [12–15]. There-
fore, HTLV-1-infected cells can express HBZ under
immunosurveillance of the host whereas Tax expression is
very restricted.
The tax and HBZ genes are encoded respectively by the
plus and minus strands of the provirus. Transcription of
these genes appears to be reciprocally controlled. In valpro-
ate-treated infected cells with high Tax expression, the HBZ
transcript was suppressed [16]. However, it is thought
that these viral genes cooperate in viral replication and in
proliferation of infected cells.4. Infection of a new individual: routes of
infection
As noted above, the infectivity of free HTLV-1 virions is very
poor, and HTLV-1 can transmit efficiently only through cell-
to-cell infection [17]. Infected cells form a virological synapse,
allowing efficient transfer of viral particles to uninfected cells,
and leading to de novo infection [3]. Therefore, the routes of
infection are limited to the following three: (i) mother-to-
child, mainly via breast-feeding, (ii) sexual transmission,
and (iii) blood transfusion or parenteral transmission
(figure 2) [7]. In all three routes, transfer of living infected
cells is essential. For transfer of infection through breast
milk, it remains unknown how infected cells pass through
the alimentary tract in the new host. It remains an open ques-
tion whether breast-duct epithelial cells contribute to HTLV-1
transmission in the breast milk [18,19]. The HTLV-1 provirus
is found mainly in effector/memory CD4þ T cells, indicating
that this subpopulation is infected with HTLV-1 [20]. Most T
cells present in breast milk and semen are effector/memory T
cells [21]. Most HBZ-expressing T cells in HBZ transgenicmice possessed the immunophenotype of effector/memory
T cells, whereas effector/memory T cells were not increased
in tax-transgenic mice [22]. Thus, HBZ changes the immuno-
phenotype of infected T cells, which facilitates transmission
of this virus.5. Spread of infection
Because primary infection with HTLV-1 is asymptomatic,
there are few data on the rate of propagation of the virus
during the establishment of the proviral load. In three recipi-
ents of organ transplants from an infected donor, the proviral
load in the circulation doubled approximately every 1.4 days
during the first few weeks of infection [23]. It is not known
whether the transient immunosuppressive treatment associ-
ated with transplantation accelerated or decreased the rate
of viral spread in these recipients.
Like other replication-competent exogenous retroviruses,
HTLV-1 can propagate by two routes [24]. First, the inte-
grated provirus is re-expressed, forming enveloped viral
particles, which infect a new cell in which the viral genome
is reverse-transcribed and the resulting double-stranded
DNA is integrated into the host genome. This may be
called the infectious route of replication. HTLV-1 has lost
the need to release cell-free virions from the infected cell:
instead, HTLV-1 spreads almost exclusively by cell-to-cell
contact via a specialized structure called the virological
synapse [3]. The cellular receptors for HTLV-1 are neuro-
pilin-1 [25] and the glucose transporter GLUT-1 [26];
heparan sulfate proteoglycans also increase the efficiency
of HTLV-1 infection [27]. Intercellular transfer of virus at
the virological synapse may occur in pockets isolated
between the two plasma membranes [28] or at the periphery
of the synapse [29]; transfer via cellular conduits has also
been proposed [30].
Second, mitosis of an HTLV-1-infected cell produces two
daughter cells that carry the provirus at the same genomic
site. In contrast to the infectious route of spread described
above, this ‘mitotic’ route involves replication of the provirus
by DNA Pol2, whose nucleotide misincorporation rate is
about 105-fold lower than that of reverse transcriptase. Mito-
tic replication therefore generates much less sequence
diversity than infectious replication.
Integration of the HTLV-1 provirus in the host genome is
not random, but is determined by factors at four successive
physical scales [31]. First, integration predominates in open,
transcriptionally-active chromatin. Second, integration is
favoured within 100 nucleotides of genomic sites that are
bound by certain proteins either directly (STAT1, TP53) or
indirectly (HDAC6, Brg1) [32]. Third, the ubiquitous
enzyme protein phosphatase 2A (PP2A) binds the complex
of HTLV-1 integrase and the viral DNA, and influences the
selection of genomic integration sites [33]. It is likely that,
as in other retroviruses such as HIV-1, certain other host pro-
teins can also bind the pre-integration complex and influence
integration site selection. Fourth, retroviral integration is tar-
geted to a primary DNA sequence motif. This DNAmotif has
been believed to be palindromic, but there is recent evidence
that the retroviral intasome recognizes a non-palindromic
motif [34]; the presence of this motif in approximately equal
numbers on both the plus and the minus strands of the
host genome generates a consensus sequence that is
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ORF IV tax(IV)
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Figure 1. Structure of HTLV-1 provirus and its encoded genes. HTLV-1 provirus
contains gag, pol, and env genes that encode structural proteins. In addition,
tax, rex, p12, p13 and p30 are transcribed from the plus strand of the provirus.
HTLV-1 bZIP factor (HBZ) is transcribed as antisense transcripts. The blue bar in
the HBZ coding region shows the CTCF binding site.
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3palindromic. Most naturally-infected T cell clones carry a
single copy of the provirus integrated into the genome [35];
it is unknown what restricts superinfection of cells with
HTLV-1.
HTLV-1 infection drives proliferation of the infected cell,
through the products of the HTLV-1 genes tax and HBZ
(see below), and certain HTLV-1-infected T-cell clones reach
a very high abundance in the circulation. Until recently, it
was believed that a typical HTLV-1-infected host carried
about 100 infected T-cell clones [36], and that the observed
oligoclonal proliferation both maintained persistence of the
virus in vivo and contributed to the pathogenesis of the
inflammatory and malignant diseases associated with
HTLV-1. Recent evidence from high-throughput sequencing
and quantification of HTLV-1 integration sites has changed
this view: the number of HTLV-1-positive T-cell clones in
the circulation in each host is of the order of 104–105 [31],
and it is the clonal diversity, not the degree of oligoclonal pro-
liferation, that correlates with the proviral load [37]. These
observations imply that high clonal diversity, rather than oli-
goclonal proliferation, predisposes to the inflammatory and
malignant diseases caused by HTLV-1.
Both CD4þ and CD8þ T cells are infected by HTLV-1:
about 95% of the proviral load is present in CD4þ T cells,
and 5% in CD8þ T cells [38]. Both CD8þ and CD4þ T cells
are preferentially infected with the virus if they are HTLV-
1-antigen-specific [11,39]. Most cell types can be infected
with HTLV-1 in vitro; small numbers of dendritic cells, mono-
cyte/macrophages and epithelial cells are infected in vivo. It
has been reported that infected dendritic cells and macro-
phages play important roles in propagation of HTLV-1 [40].6. Human T-cell leukaemia virus type 2
Human T-cell leukaemia virus type 2 (HTLV-2) was discov-
ered in a T-cell line established from a patient with T-cell
variant hairy cell leukaemia [41]. However, an association
between HTLV-2 and leukaemia has not been established,
and it is now thought that HTLV-2 does not cause leukaemia.
HTLV-2 encodes Tax-2, whose sequence is similar to that of
HTLV-1 Tax. In addition, HTLV-2 encodes the antisenseprotein of HTLV-2 (APH-2) on the minus strand of the pro-
virus [42]. However, unlike HBZ, APH-2 does not have
growth-promoting activity [43]. HTLV-2 almost exclusively
infects CD8þ T cells in vivo [38], whereas HTLV-1 is present
mainly in CD4þ T cells. However, the precise mechanisms
of cell specificity of HTLV-1 and HTLV-2 remain to be
elucidated.7. Immune response to human T-cell leukaemia
virus type 1
The immune response to HTLV-1 has been extensively
reviewed elsewhere [44–46], and will be summarized briefly
here.
(a) Host restriction factors
Efficient spread of HTLV-1 virions across the intimate cell–cell
contact in the virological synapse minimizes the ability of
tetherin to inhibit HTLV-1 propagation [47]. The deaminase
APOBEC3G, which plays an important role in restricting lenti-
viral infections, also has activity against HTLV-1. APOBEC3G
can generate nonsense mutations in vivo, but since it targets the
minus strand during reverse transcription, it spares HBZ [48];
the consequent silencing of plus-strand gene products and
sustained HBZ expression may favour viral persistence. Like
HIV-1, HTLV-1 incorporates APOBEC3G into the virion,
but this incorporation is limited by a peptide motif in the
nucleocapsid [49].
SAMHD1, which limits the supply of nucleoside triphos-
phates for virion replication, inhibits HTLV-1 infection of
macrophages [50]. Type 1 interferon has activity against
HTLV-1, but the virus suppresses Type 1 interferon pro-
duction both by inducing the cytokine suppressor SOCS1
[51] and by Tax protein-mediated inhibition of RIG-I and
MDA5 [52]. However, HTLV-1 Tax strongly induces inter-
feron-g production by the infected cell [53], and chronic
stimulation of interferon response genes is associated with
the inflammatory disease HAM/TSP [54].
(b) Lymphocyte response to human T-cell leukaemia
virus type 1
The frequency and activity of NK and NKT-like cells are
abnormally low in HAM/TSP [55–57], but the significance
of this reproducible observation is not understood. The
HLA Class 1-restricted CD8þ CTL plays a dominant role in
host protection in most viral infections, and the CTL response
is an important determinant of the outcome of HTLV-1 infec-
tion. HTLV-1-infected individuals typically have a high
frequency of persistently activated, HTLV-1-specific CTLs in
the circulation; the activated state indicates recent exposure
to newly synthesized viral antigen, and therefore demon-
strates that the virus is persistently expressed in vivo.
Although the Tax protein is highly immunodominant in the
anti-HTLV-1 CTL response, it is the efficacy or ‘quality’ of
the CTL response to the HBZ protein that is associated
with control of the virus in vivo [14]. The class 1 HLA geno-
type of the host, which determines the antigen specificity and
quality of the CTL response, therefore determines the proviral
load and the risk of HAM/TSP [44]; in southern Japan, HLA-
A*02 and Cw*08 are associated with protection against
HAM/TSP, whereas HLA-B*54 is associated with a higher
asymptomatic
carrier
(95%)
HTLV-1-
infected cells
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Figure 2. Natural history of HTLV-1 infection. HTLV-1 transmits via three different routes: (i) breast-feeding, (ii) sexual intercourse, and (iii) the parenteral route.
After infection, the virus increases the number of infected cells in vivo through the actions of Tax and HBZ. The host immune response suppresses HTLV-1-infected
cells, mainly through lysis by virus-specific cytotoxic T lymphocytes (CTLs). HTLV-1-infected cells possess the immunophenotype of effector/memory T cells, which
migrate into breast milk and semen; these infected cells can transfer infection to the new host. Between 5% and 10% of HTLV-1-infected individuals develop ATL or
inflammatory diseases. STD, sexually transmitted disease.
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4risk of the disease [58]. For reasons that are not yet under-
stood, the killer immunoglobulin-like receptor KIR2DL2
enhances both the protective (HLA-A*02) and the pathogenic
(HLA-B*54) HLA Class 1-associated effects in HTLV-1
infection [59].
The frequency of HTLV-1-specific CD4þ T cells is signifi-
cantly higher in patients with HAM/TSP than in
asymptomatic carriers of the virus. CD4þ T cells predominate
in the early, active lesions in the central nervous system in
HAM/TSP [60], and the predominantly Th1 response is
likely to contribute to the pathogenesis of HAM/TSP [54,61].
HTLV-1 Tax protein induces the infected CD4þ T cell to
secrete the chemokine CCL22, which maintains a high fre-
quency of CD4þ Foxp3þ cells in the circulation because
these cells characteristically express the CCL22 receptor,
CCR4 [62]. The regulatory phenotype of the Foxp3þ cells
may diminish the protective effect of the anti-HTLV-1 CTL
response [63]. Although adult T-cell leukaemia cells fre-
quently express Foxp3, ATL is not necessarily a tumour of
regulatory T cells [64,65].8. Mechanisms of viral persistence in the chronic
phase of infection
(a) Roles of HBZ and Tax in maintaining clonal
longevity and cell turnover
After infection, HTLV-1 increases the proviral load mainly by
driving proliferation of infected cells (mitotic division)
[66,67]. Indeed, inhibitors of reverse transcriptase or integrase
did not change the proviral load in HTLV-1-infected individ-
uals, indicating that de novo infection does not contribute
significantly to the proviral load in the chronic phase [68].HBZ and Tax play critical roles to maintain clonal longevity.
HBZ perturbs the localization and function of FoxO3a, a criti-
cal transcriptional activator of the genes encoding Bim and
also Fas ligand, which results in inhibited apoptosis [69].
HBZ also interacts with the Rb/E2F-1 complex and promotes
cell cycle progression [70]. Furthermore, HBZ determines the
immunophenotype of infected cells, including ATL cells:
HBZ induces expression on the cell surface of TIGIT and
CCR4 [71,72], which are implicated in the infiltration and
proliferation of HTLV-1-infected cells.
In addition to these functions of HBZ protein, HBZ RNA
possesses functions that are distinct from those of its protein.
HBZ RNA is more strongly retained in the nucleus than the
other viral gene transcripts. HBZ RNA inhibits apoptosis,
and promotes proliferation of expressing cells [73,74]. These
mechanisms could reduce production of HBZ protein,
which is recognized by the host immune system.
Tax strongly activates NFkB, which leads to expression of
the anti-apoptotic gene c-FLIP [75,76] and genes associated
with cell cycling including cyclin D2, cyclin E, E2F1, CDK2,
CDK4 and CDK6 [77]. In addition, Tax promotes cell prolifer-
ation and cell cycling through activation of the PI3 K/Akt
pathway [78]. Thus, Tax also inhibits apoptosis and promotes
cell proliferation. The function of Tax is impaired by tran-
scription factors in the classical Wnt pathway, TCF-1/
LEF-1, in the thymus [79]. However, expression of TCF-1/
LEF-1 is suppressed in effector/memory T cells, indicating
that Tax can function in these cells, so enabling HTLV-1 to
persist in peripheral effector/memory T cells in vivo.(b) Regulation of proviral latency in vivo
The HBZ gene is persistently expressed at a low level in
most—if not all—infected cells in vivo [73]. The plus-strand
rstb.royalsocietypublishing.org
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5products are usually undetectable in freshly isolated periph-
eral blood mononuclear cells (PBMCs) but, as noted above,
the persistently activated CTL response to Tax, Pol and Gag
indicates that these antigens are frequently expressed
in vivo. It is unknown what regulates this differential expression
of plus and minus strands and, in particular, the frequency,
intensity and duration of what are presumably bursts of
plus-strand expression.
Taniguchi et al. [80] showed that DNA methylation might
explain the proviral silencing in vivo, but they also observed
an unexplained border in the methylation in the pX region
of the provirus. It has now been shown [81] that CTCF, the
key chromatin architectural protein and insulator-binding
protein, binds to the provirus at its epigenetic border, at
which the pattern of several other epigenetic marks also
changes. It is possible that CTCF binding, which may be
reversible, allows temporary silencing of plus-strand
expression at the same time as persistent negative-strand
(HBZ) expression. Another major function of CTCF is to
form chromatin loops, both to organize the chromatin struc-
ture and to bring enhancers near their cognate promoters.
The abnormal CTCF-binding site present in the HTLV-1 pro-
virus can indeed form loops with flanking host chromatin
[81]; this looping may contribute to leukaemogenesis by
allowing LTR-mediated activation of host genes (see below).
The genomic integration site influences the expression of
the provirus, and consequently each infected T-cell clone
will have its own characteristics of proviral expression. Two
chief specific features of the integration site are associated
with the regulation of plus-strand expression [32]. First,
proximity (within 100 base pairs) to certain transcription fac-
tors that bind to chromatin either directly (STAT1, P53) or
indirectly (HDAC6, BRG1). The mechanistic explanation for
these observations is not yet known. Second, the orientation
of the provirus relative to the transcriptional orientation of
the nearest host gene. The presence of a host promoter in
the same transcriptional sense upstream of the 50LTR is
associated with transcriptional silencing of the HTLV-1 plus
strand, whereas a host promoter upstream of the 30LTR (in
the same sense as the proviral negative strand) is associated
with activation of plus-strand expression. These observations
suggest that transcriptional interference plays a part in
regulating HTLV-1 proviral latency.
Two central questions remain in the regulation of HTLV-1
proviral latency. First, what causes (or allows) the rapid spon-
taneous transcriptional activation of the proviruswhen PBMCs
are taken ex vivo? The answer to this question will illuminate
the mechanisms that maintain plus-strand latency in vivo.
Second, what are the molecular mechanisms that give rise to
cell-to-cell heterogeneity in proviral expression, and what is
the importance of this heterogeneity in viral persistence?
(c) Structure and dynamics of human T-cell leukaemia
virus type 1 clonality in vivo
It was formerly believed that a typical host possessed about
100 clones of HTLV-1-infected T cells [36], and that the
most abundant (‘oligoclonally expanded’) clones accounted
for the Tax expression, the high proviral load and the
HTLV-1-associated diseases [82,83]. However, quantitative
high-throughput analysis has revealed a very different pic-
ture. The number of clones carried by each host is usually
between 104 and 105 (ranging from 103 to 106). It is thelarge number of low-abundance clones that constitute the
high proviral load [37]: these clones frequently express Tax,
and turn over rapidly in vivo.
The current picture of HTLV-1 clonality is depicted sche-
matically in figure 3. We postulate that constant pressure
exerted by the host immune response limits infectious spread
during the chronic phase of infection, and selects for persist-
ence of clones with an optimal pattern of proviral expression.
This optimal pattern consists of minimal but persistent HBZ
expression, and bursts of plus-strand expression that may be
driven by cellular stress, such as when lymphocytes are trans-
ferred between individuals, to promote viral transmission. The
CTL response to the HBZ protein limits the proviral load;
the virus minimizes the effect of this force by restricting the
expression and the translation of HBZ mRNA and the immu-
nogenicity of the HBZ protein. Once the proviral load
set-point (quasi-equilibrium) is reached, the rate of establish-
ment of new long-lived clones is likely to be restricted by the
CTL response to HBZ, Tax and other viral antigens, and by
competition for resources with pre-existing clones.9. Mechanisms of oncogenesis
For many years, the Tax protein was believed to be necessary
and sufficient to cause malignant transformation of HTLV-1-
infected cells. Transduction of Tax-expressing vectors can
immortalize T cells in vitro [91,92], and transgenic expression
of Tax induced cancers in vivo. However, the cell type of the
cancer caused by Tax depended on the promoter. Tax
expression by the granzyme B promoter induced a tumour
of NK cells [93], whereas pX expression driven by the
H-2Kd promoter caused breast cancers [94]. Thus, these
findings indicate that high or persistent expression of Tax is
oncogenic. However, several more recent lines of evidence
suggest that, in natural HTLV-1 infection, HBZ rather than
Tax is the critical element in HTLV-1 oncogenesis.
The most direct evidence of HTLV-1 infection in ATL cells
is the presence of the monoclonally integrated provirus.
Therefore, analysis of the structure and genomic integration
site of HTLV-1 proviruses in ATL cells can provide critical
clues on leukaemogenesis by HTLV-1. Studies of HTLV-1
proviruses and transcripts of viral genes showed that ATL
cells do not express Tax in approximately half the cases of
ATL. There are three known mechanisms to inactivate Tax
expression: (i) nonsense mutations of the tax gene, (ii) DNA
methylation of the 50LTR, and (iii) deletion of the 50LTR.
However, HBZ is expressed in all ATL cases, suggesting
that HBZ is indispensable. DNA methylation of the 50LTR
accumulates during the natural course of infection, which
finally silences transcription of the sense strand from the
50LTR [95]. However, DNA methylation does not extend to
the pX region and the 30LTR [80], which is critical for HBZ
transcription. Recently, a CTCF-binding region was found
in the pX region, which may account for the arrest of DNA
methylation before pX and 30LTR, and ensure continued
HBZ expression [81]. Furthermore, the malignant clone in
some cases of ATL contains a defective provirus that lacks
the 50LTR (type 2 defective provirus) which is generated
before genomic integration of the provirus [96]. The lack of
the 50LTR precludes expression of Tax in some cases.
Nonsense mutations of the tax gene were found in
approximately 10% of ATL cases. There is a hotspot of
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Figure 3. Schematic depiction of HTLV-1 clonality over the course of infec-
tion. Each line on the figure represents the growth of one HTLV-1þ T-cell
clone; the grey shaded area represents a large number of lower-abundance
clones. The red dashed line shows the growth trajectory of a clone that
undergoes malignant transformation after 50 years; the red asterisks
denote the acquisition of tumour driver mutations; in ATL these are frequent
in certain signalling pathways: T-cell receptor; NFkB; CCR4; p53; and Notch-1
[84–87]. The pre-malignant clone is shown to originate in early infection;
this is likely [31,88], but not necessary. During the first few weeks of infec-
tion, before the emergence of an effective cytotoxic T-lymphocyte response,
the virus spreads rapidly by cell-to-cell contact through the virological
synapse; the number of clones of infected T lymphocytes typically rises to
104 to 105 when the proviral load set-point is reached, after approximately
one to two months [23,89]. In the chronic phase of infection, CTLs restrict
this infectious mode of spread [44], and the proviral load is maintained
by continued proliferation of existing clones. In this phase, there is a
quasi-equilibrium between viral propagation and the host immune response;
while the proviral load remains approximately constant, the abundant clones
grow in abundance and the low-abundance clones shrink, leading to a pro-
gressive rise in the oligoclonality index [37]. The abundant clones appear to
last for the lifetime of the host [37]. During chronic infection the abundant,
persistently activated anti-Tax CTL response demonstrates that Tax expression
is frequent in vivo [45]. Since Tax expression is normally undetectable in fresh
PBMCs, we infer that Tax expression is intermittent in vivo. Virus-specific CTLs
may persist during active ATL; it remains to be tested whether boosting the
CTL response can be used as an adjunct to therapy. Constant cell division
leads to the accumulation of replicative mutations, which increase the prob-
ability of malignant transformation [90]. ATL usually arises after 4–6 decades
of infection, and so is more frequent in individuals infected during childhood.
The risk of ATL may also be correlated with the proviral load, which in turn is
correlated with the number of HTLV-1-infected T-cell clones, not with the
degree of oligoclonality [37].
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Figure 4. Leukaemogenesis by viral genes, genetic and epigenetic altera-
tions. About 5% of HTLV-1-infected individuals develop ATL after a long
latent period. (a) Tax and HBZ play critical roles in leukaemogenesis by
HTLV-1. HBZ is constantly expressed while the tax gene is sporadically tran-
scribed. Tax and HBZ modulate the immunophenotype of ATL cells, inhibit
apoptosis and promote proliferation. HBZ is expressed in all ATL cases
while tax is not expressed in approximately half of ATL cases. (b) Subsequent
genetic and epigenetic alterations that accumulate during the long lifetime of
the infected clone fix or potentiate these phenotypic and functional changes.
(c) For example, HBZ induces CCR4 expression, which leads to increased
migration and proliferation of infected cells. Gain-of-function mutations of
CCR4 were found in approximately 20% of ATL cases. Similarly, Tax strongly
activates NFkB. Increased miR31 expression leads to NFkB activation in the
absence of Tax.
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6nonsense mutations in the HTLV-1 provirus in a target
sequence of APOBEC3G [48], suggesting that these nonsense
mutations are generated by APOBEC3G during reverse tran-
scription. Furthermore, this nonsense mutation of the tax
gene was found in some asymptomatic carriers [48]. These
findings demonstrate that nonsense mutations are generated
before infection, and HTLV-1-infected cells carrying a non-
sense mutation in the tax gene can transform to ATL cells,
suggesting that HBZ plays critical roles in oncogenesis.
A long latent period is necessary before onset of ATL,
suggesting that multiple genetic and epigenetic alterations
are needed for ATL (figure 4). Recently, extensive studies of
genomes in ATL cells revealed the landscape of genetic and
epigenetic changes [84]. Interestingly, genetic alterations
accumulated in the genes associated with pathways that
Tax and HBZ target. These findings suggest the following
scenario. HTLV-1-infected clones persist and proliferatein vivo through the actions of HBZ and Tax during asympto-
matic carriage of the virus. Thereafter, genetic and epigenetic
alterations fix or potentiate these changes. For example, HBZ
induces CCR4 expression [72]. Gain-of-function mutations of
the CCR4 gene are associated with proliferation and infiltra-
tion of ATL cells (figure 4) [84,85]. Furthermore, Tax strongly
activates the NFkB pathway. Expression of miR31 enhances
NFkB in ATL cells even in the absence of Tax [97]. These tar-
gets of viral proteins and mutations are important for therapy
in ATL.10. Strategies to prevent and treat adult T-cell
leukaemia-lymphoma
(a) Current approaches to management of adult T-cell
leukaemia-lymphoma
There are four subtypes of ATL according to clinical criteria:
acute, lymphoma-type, chronic and smouldering types [98].
In general, patients with acute, lymphoma-type or unfavour-
able chronic type ATL are treated, whereas patients with
typical chronic or smouldering ATL are carefully observed.
ATL patients are usually treated with combination chemo-
therapy including VCAP-AMP-VECP (also known as
LSG15) therapy, or CHOP therapy. However, the prognosis
of these patients remains poor despite intensive chemother-
apy. On the other hand, some patients who received
haematopoietic stem cell transplantation have achieved
long-term survival [99]. It has been reported that anti-viral
immunity was enhanced in these patients, which suggests
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7the use of immunotherapy as an adjunct to the treatment of
ATL [100].
It has been reported that sustained treatment with azi-
dothymidine (AZT) plus interferon-a can be effective in
cases of ATL of the leukaemic types, but is less effective
in the lymphoma type [101]. Although AZT is a reverse
transcriptase inhibitor, the combination of AZT with inter-
feron-a does not impair HTLV-1 replication; this therapy
acts through a mechanism other than anti-viral activity
[102] that is not yet understood. Combination therapy using
arsenic trioxide, interferon-a and zidovudine was reported
to be effective in chronic ATL patients [103].
Most HTLV-1 infected cells and ATL cells express the che-
mokine receptor CCR4 on their surfaces [104]. CCR4
expression is implicated in migration and proliferation of T
cells. Recently, it has been reported that HBZ induces CCR4
expression through enhanced GATA3 transcription [72]. An
anti-CCR4 monoclonal antibody, mogamulizumab, has been
developed for treatment of ATL patients [105]. Antibody-
dependent cell-mediated cytotoxicity (ADCC) is thought to
be a major mechanism by which this antibody strongly sup-
presses ATL in vivo [106]. CCR4 is also expressed on active
regulatory T (Treg) cells [107]. After administration of moga-
mulizumab, ATL cells were suppressed by ADCC exerted
by NK cells. At the same time, anti-Tax and anti-HBZ CTLs
were activated in these patients, which possibly suppress
proliferation of ATL cells [108]. Thus, the anti-CCR4
antibody exerts dual beneficial functions in vivo, which may
account for the prolonged suppressive effect of this antibody
on ATL cells.(b) Possible future approaches to management of adult
T-cell leukaemia-lymphoma
As discussed above, HTLV-1 persists in vivo during chronic
infection mainly by sustained proliferation of infected cells.
The high resulting proviral load is also critical in the trans-
mission of the virus, which requires transfer of infected
cells to the new host. Therefore, a logical strategy to prevent
ATL is to reduce the number of infected cells. Immune
responses, primarily CTLs, strongly suppress proliferation
of ATL cells and HTLV-1-infected cells. Thus, vaccines
against Tax and HBZ might be effective in preventing
HTLV-1-associated diseases. In addition, the recent genetic
and epigenetic analyses of ATL cells reveal critical pathways
and molecules for ATL. Therapy targeted to these pathways
might improve the prognosis of this intractable disease.Data accessibility. This article has no additional data.
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